A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

NCT01340053 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
186
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Ardelyx